Clinical Study on Compound Sophorae Flavescentis Radix (Kushen) Injection Combined with Intraperitoneal Chemotherapy for Advanced Ovarian Cancer with Malignant Ascites
10.3969/j.issn.1005-5304.2015.05.008
- VernacularTitle:复方苦参注射液配合腹腔灌注化疗治疗卵巢癌腹腔积液临床研究
- Author:
Yuan WANG
- Publication Type:Journal Article
- Keywords:
compound Sophorae Flavescentis Radix (Kushen) injection;
ovarian cancer with malignant ascites;
intraperitoneal chemotherapy;
clinical study
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2015;(5):25-28
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of compound Sophorae Flavescentis Radix (Kushen) injection intravenous drip combining carboplatin intraperitoneal injection in treating advanced ovarian cancer with malignant ascites. Methods Totally 160 patients with advanced ovarian cancer with malignant ascites were randomly divided into compound Kushen injection intravenous drip combining carboplatin intraperitoneal injection group (observation group) and carboplatin intraperitoneal injection group (control group). Clinical efficacy observation and evaluation were conducted from malignant ascites condition, changes in living quality (KPS score), T lymphocytes subsets and changes of the NK cells in blood samples, pain-relieving efficacy, and toxicity response. Results There were significant differences in malignant ascites between the two groups (P<0.05), with treatment group showing better improvement than the control group. In improving quality of life, the observation group had precedence over the control group (P<0.01). After treatment, CD3+, CD4+, CD4+/CD8+, NK (CD16+CD56+) in control group were obviously less than the observation group (P<0.05). The pain-relieving efficacy in the observation group was superior to that in the control group. Compared with the control group, the observation group had less gastrointestinal reaction and bone marrow suppression, with statistical significance (P<0.05). Conclusion Compound Kushen injection intravenous drip combined with carboplatin intraperitoneal injection in treating advanced ovarian cancer with malignant ascites can effectively improve the immune function and quality of life, and can be used for adjuvant chemotherapy with less side effects.
